Biomarkers in differentiating clinical dengue cases: A prospective cohort study

Gary Kim Kuan Low1*, Seng Chiew Gan2, Shu Cheow Ho3

1Department of Population Medicine, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Bandar Sungai Long, Malaysia
2Department of Pre-clinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Bandar Sungai Long, Malaysia
3Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Bandar Sungai Long, Malaysia

ARTICLE INFO

Article history:
Received 10 Aug 2015
Accepted 15 Oct 2015
Available online 9 Dec 2015

Keywords:
Severe dengue
Warning signs
Vascular endothelial growth factor-A
Neopterin
Pentraxin 3
Soluble vascular cell adhesion molecule 1
Thrombomodulin

ABSTRACT

Objective: To evaluate five biomarkers (neopterin, vascular endothelial growth factor-A, thrombomodulin, soluble vascular cell adhesion molecule 1 and pentraxin 3) in differentiating clinical dengue cases.

Methods: A prospective cohort study was conducted whereby the blood samples were obtained at day of presentation and the final diagnosis were obtained at the end of patients’ follow-up. All patients included in the study were 15 years old or older, not pregnant, not infected by dengue previously and did not have cancer, autoimmune or haematological disorder. Median test was performed to compare the biomarker levels. A subgroup Mann-Whitney U test was analysed between severe dengue and non-severe dengue cases. Monte Carlo method was used to estimate the 2-tailed probability (P) value for independent variables with unequal number of patients.

Results: All biomarkers except thrombomodulin has P value < 0.001 in differentiating among the healthy subjects, non-dengue fever, dengue without warning signs and dengue with warning signs/severe dengue. Subgroup analysis for all the biomarkers between severe dengue and non-severe dengue cases was not statistically significant except vascular endothelial growth factor-A (P < 0.05).

Conclusions: Certain biomarkers were able to differentiate the clinical dengue cases. This could be potentially useful in classifying and determining the severity of dengue infected patients in the hospital.

1. Introduction

Only nine countries had experienced severe dengue epidemics before the year of 1970. The disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific. More than 3.9 billion people, who constitute 40% of the world population, are at risk to the exposure of dengue infection[1]. The incidence rate is approximately four times higher in 15 year-old and above as compared to less than 15 year-old Malaysians[2]. This has an impact on the economy of the country’s health care system.

Dengue clinical manifestation is divided into three phases: febrile, critical and recovery phase. Critical phase is the most important phase where the patient can either recover or die from the disease[3-5]. Unfortunately, critical phase is difficult to predict even with the new World Health Organization classification which hope to serve better clinical management of the patient[6,7]. This led to unnecessary admission and in turn increased the health care burden due to the lack of specificity of warning signs[8]. The criteria of severe dengue in the revised classification indicate that the pathological changes have already occurred and thus only a short window period for treatment and intervention. The list of warning signs were based on symptoms and signs one day prior to the cases that requiring major intervention[7]. This also does not allow clinician to timely institute the treatment within the short time frame. Furthermore, a significant 14% of patients with severe dengue do not develop warning signs at all[9].

In order to reduce the burden of the disease and for safer management of dengue infected patients, a prediction method is useful to help guide the clinicians. Numerous biomarkers for dengue infection were identified for the prediction of dengue infection and its progress[10,11]. Unfortunately, these markers have not been substantiated so that it could be applied in the prediction of the infection and its outcome. The selection of biomarkers was based on future use at primary care setting with test kit that is cheap and easily to be performed in a large population. Therefore, biomarkers which tested using ELISA technique
along with literature evidence to indicate its use in dengue infection were selected[12-19]. Hence, this study identified five most potential biomarkers [neopterin, vascular endothelial growth factor-A (VEGF), thrombomodulin, soluble vascular cell adhesion molecule 1 (VCAM-1) and pentraxin 3 (PTX-3)] to be evaluated in differentiating clinical dengue cases. The secondary objective was to compare the different clinical dengue cases with healthy subjects and non-dengue fever.

2. Material and methods

2.1. Sample collection

This was a prospective cohort study conducted in Ampang Hospital from January to September 2014 where patients were recruited consecutively at day of presentation and upon discharged from the hospital. Informed consent and patient information leaflet were provided to all patients. This study was approved by the Medical Research and Ethics Committee (National Institute of Health Secretariat, Malaysia) and Scientific and Ethical Review Committee of Universiti Tunku Abdul Rahman.

The blood samples were obtained at the day of presentation. The demography and final diagnosis of the patients were obtained from the medical records at the end of patient follow-up with the hospital. The levels of the biomarkers were compared among healthy subjects, non-dengue fever, dengue without warning signs and dengue with warning signs/severe dengue. The clinical classification of dengue infection was based on clinical practice guidelines published by World Health Organization[6].

All patients included in the study were 15 years old or older, not pregnant, has not been infected by dengue before (secondary dengue) and did not have autoimmune disorder, haematological disorder or cancer. All healthy subjects which derived mainly from university students and some were staffs working in the hospital, did not have fever at the time when blood was taken. Non-dengue fever was defined as patients having fever but did not have the final diagnosis of dengue such as upper respiratory tract infection, acute gastroenteritis and pneumonia. The sample size of 95 per group with a power of 80% were based on the highest calculated sample size using previous available studies of various biomarkers[12,16,18].

2.2. Blood sampling and biomarkers assay

The blood samples were obtained either by the investigator or by the attending practitioners. Plain tubes and ethylene diamine tetraacetic acid tubes were used for the collection of blood samples. The serum of the blood samples was stored below -20 °C. The duration of storage to the analysis of blood samples were around 8 to 12 months. Ideally the laboratory analysis should be performed immediately to avoid degradation of biomarkers. The laboratory analysis was unable to be performed much earlier because the different test kits from different company did not arrived to our laboratory at the same time. The five test kits were chosen to be performed together rather than individually to avoid repeated freeze-thaw cycle which could lead to degradation of biomarkers as well. The results of this study produced significant finding even though the test were performed at 8 to 12 months’ time. The biomarkers were expected to be degraded equally in all samples since they were tested around the same time which allows better comparison.

The levels of the biomarkers were measured using commercially available sandwich ELISA test kits: neopterin (IBL International), VEGF (eBioscience and R&D Systems), VCAM-1 (eBioscience and R&D Systems), thrombomodulin (R&D Systems) and PTX-3 (R&D Systems).

2.3. Statistical analysis

The demography (age, sex and race), day of fever when the blood was taken, dependent variables (healthy subjects, non-dengue fever, dengue without warning signs and dengue with warning signs/severe dengue) and independent variables (levels of the biomarker) were described.

The median test was used when the distribution of the biomarker levels among the dependent variables were not similar as indicated by the non-parametric Levene test. A subgroup Mann-Whitney test was analysed by splitting the severe dengue cases from dengue with warning signs to compare severe dengue within-severe dengue cases (combined dengue with and without warning signs). Monte Carlo method was used to estimate the 2-tailed probability (p) value for independent variables with unequal number of patients. A p-value of less than 0.05 is considered statistically significant. SPSS (Statistical Package for Social Science) version 20 was used in the analysis.

3. Results

The median age was 25 years old with interquartile range (IQR) of 12. Number of patients included in the study was 195 (56.7%) male and 149 (43.3%) female. There were 230 (66.9%) Malays, 85 (24.7%) Chinese, 23 (6.7%) Indians and 6 (1.7%) Malaysians of other ethnicity. The median day of fever when the blood was taken was Day 4 of fever (IQR: 2 days). Missing biomarker levels were found one each in thrombomodulin and VCAM-1, and three in PTX-3. The median, IQR and number of patients of the five biomarkers stratified by the groups of dependent variable were shown in Table 1.

Comparison of neopterin, VEGF, thrombomodulin, VCAM-1 and PTX-3 levels among the dependent variables along with the post-hoc analysis was tabulated in Table 2. Subgroup analysis for all the biomarkers between severe dengue and non-severe dengue was not statistically significant except VEGF (P < 0.05) as in Table 3.

Table 3

| Biomarkers [median (IQR)] | Mean rank | Mann-Whitney U | P value |
|--------------------------|-----------|----------------|---------|
| Neopterin (nmol/L)       | 91.56     | 118.20         | 623.00  | 0.13    |
| VEGF (pg/mL)             | 91.23     | 124.00         | 565.00  | <0.05   |
| Thrombomodulin (pg/mL)   | 93.38     | 77.15          | 716.50  | 0.35    |
| VCAM-1 (ng/mL)           | 94.32     | 60.75          | 552.50  | 0.05    |
| PTX-3 (ng/mL)            | 89.72     | 122.10         | 554.00  | 0.06    |

* Monte Carlo method.
Table 2
Comparison of the biomarker levels among the dependent variables: healthy subjects, non-dengue fever, dengue without warning signs and dengue with warning signs/severe dengue.

| Biomarker            | Median | Chi-square (df) | P-value | Healthy subjects, non-dengue fever | Non-dengue fever, dengue without warning signs | Dengue without warning signs, dengue with warning signs |
|----------------------|--------|-----------------|---------|-----------------------------------|-----------------------------------------------|-----------------------------------------------------|
| Neopterin (nmol/L)   | 55.61  | 38.75 (3)       | < 0.001 | 12.02 (1)                         | 1.36 (1)                                      | 4.26 (1)                                            |
| VEGF (gg/mL)         | 0.00   | 17.73 (3)       | < 0.001 | 1.33 (1)                          | 17.16 (1)*                                    | 4.23 (1)*                                           |
| Thrombomodulin (gg/mL)| 4.432.33| 2.66 (3)        | 0.450   | 0.03 (1)                          | 0.41 (1)                                      | 0.79 (1)                                            |
| VCAM-1 (ng/mL)       | 123.33 | 57.19 (3)       | < 0.001 | 1.64 (1)                          | 29.91 (1)*                                    | 0.91 (1)                                            |
| PTX-3 (ng/mL)        | 3.88   | 30.13 (3)       | < 0.001 | 4.46 (1)*                         | 3.57 (1)                                      | 2.82 (1)                                            |

* Median test; *P < 0.05 with non-dengue fever has higher biomarker level than healthy subjects; dengue with warning signs has higher biomarker level than dengue without warning signs; **P < 0.001 with non-dengue fever has higher biomarker level than healthy subjects, dengue without warning signs has higher biomarker level than non-dengue fever; *P < 0.001 with non-dengue fever has higher biomarker level than dengue without warning signs.

4. Discussion

Neopterin and PTX-3 levels have a clear increasing median trend from healthy subjects to severe dengue. All except thrombomodulin have statistically significant difference among the four groups of dependent variable. The post-hoc analysis indicated that these biomarkers were able to discriminate certain groups of dependent variables. Subgroup analysis between severe dengue and non-severe dengue cases indicated that only VEGF was able to discriminate the two categories. Though VCAM-1 and PTX-3 were not statistically significant, the P values were at the margin of the pre-determined P value of less than 0.05. However, VCAM-1 has a lower level in severe dengue compared to non-severe dengue cases which was not theoretical coherent.

Analysis of neopterin appeared to be consistent with previous studies where the serum neopterin could differentiate dengue fever from dengue haemorrhagic fever/dengue shock syndrome and dengue infection from healthy individuals[12,13]. Other studies have shown that neopterin is a non-specific biomarker which its level also elevated in other conditions such as cardiovascular disease, pneumonia and colorectal cancer[20-22]. Hence, this could possibly explain the failure to differentiate between non-dengue fever and dengue without warning signs in our study. Another possible explanation is that neopterin is only elevated during the plasma leakage which is seen in dengue with warning signs[23].

Similar to some studies, VEGF levels could not differentiate between the healthy subjects, non-dengue fever and dengue without warning signs[24,25]. However, VEGF is elevated in dengue with warning signs/severe dengue[26], but care must be taken when comparing with studies conducted in children[27-29].

Our study on thrombomodulin level in dengue infection is in agreement with some studies where thrombomodulin could not differentiate the clinical dengue cases[24,30], but not in many other studies[14,18,19,30-33]. However, those studies conducted were in children which itself is a higher risk of severe complication and thus reflected in the elevated thrombomodulin levels[14,18,19,31].

VCAM-1 was only able to differentiate dengue without warnings signs from non-dengue fever. As opposed to previous study, VCAM-1 could not differentiate among the different severity of dengue cases in our study[34]. Other studies were conducted in children indicated VCAM-1 could differentiate the different severity of dengue cases[17,35,36].

To our knowledge, our study was the first to evaluate PTX-3 in dengue infection of adult population. There was a study conducted in children with similar results whereby the levels of PTX-3 were higher in dengue shock syndrome compared to dengue fever/dengue haemorrhagic fever in the first five days of admission[37].

Several limitations identified in this study: (i) the inclusion criteria was based on the clinical diagnoses made by the attending practitioners, not by the laboratory diagnosis. There could be misclassification among the non-dengue fever and dengue fever cases. Ideally, it should be supplement with a confirmatory dengue diagnosis. (ii) the day of diagnosis made especially to those who developed severe dengue should be noted down. There is a possibility that the blood withdrawn from the patients coincided with the same day as the diagnosis being made. Furthermore, the blood was taken at around day four of fever in our study coincides during the critical phase of dengue infection. Hence, this study’s result might not be able to predict severe dengue.

(iii) the sample size for severe dengue in the subgroup analysis was low as this was not the primary objective of this study. (iv) there could be variation among the commercial test kit used. However, few of the same samples were tested in each subsequent test kit to ensure the results were reliable. For those test kits were not consistent, all the samples were repeated in subsequent test kits. (v) this study was conducted in a hospital setting and therefore, it is expected to have much severe cases compared to primary care clinics. The result is perhaps applicable to the hospital population.

In our study, only 10 cases of all dengue cases (5.7%) progressed to severe dengue which was also seen in previous study[37]. Hence, the study should have focused on group of patients developing complication instead of warning signs because many of the patients with warning signs do not progress to severe dengue. Perhaps, the recovery of these patients who do not progress to severe dengue could also be due to the supportive treatment provided after admitting to the hospital. The subgroup analysis indicated that VEGF and PTX-3 could be a potential biomarker in differentiating severe dengue cases from non-severe dengue cases. The results though favourable, the results should be interpreted cautiously as mentioned in the limitation of the study: blood could have been taken during the same day as the diagnosis being made whereby the pathogenesis of complication has already begun. This will not be helpful in predicting the severity of dengue infection.Since these biomarkers were also non-specific to dengue infection, the use of biomarkers in suspected dengue patient should be accompanied by a diagnostic test. Otherwise, non-dengue fever cases could be misdiagnosed as dengue which will in turn affect the treatment and the disease outcome. Thus, further appropriate study to address the limitations is to be conducted before concluding that the results were favourable in clinical management of dengue infection.

In conclusion, some of the biomarkers were able to differentiate the clinical dengue cases. This could be potentially useful in classifying and determining the severity of dengue infected patients in the hospital.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

The authors would like to thank the Director General of Health Malaysia for permission to publish this paper. We would also thank the Director, Head of Emergency Department of Ampang Hospital and medical assistants who facilitated this study. This work was supported by Universiti Tunku Abdul Rahman Research Fund [IPSR/RMC/
References

[1] World Health Organization. Dengue and severe dengue. Fact sheet No. 117. Geneva: World Health Organization; 2015. [Online] Available from: http://www.who.int/mediacentre/factsheets/fs117/en/ [Accessed on 29th July, 2015]

[2] Ministry of Health. Clinical practice guidelines: management of dengue infection in adults. 2nd ed. Putrajaya: CPG Secretariat, Health Technology Assessment Section, Medical Development Division, Ministry of Health Malaysia; 2010. [Online] Available from: http://www.moh.gov.my/attachments/5502.pdf [Accessed on 7th August, 2013]

[3] Nishiyama H, Halstead SB. Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis 2007; 195: 1007-13.

[4] Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11(3): 480-96.

[5] Rigau-Pérez JG, Clark GG, Gubler DJ, Sanders EJ, Vornadom AV. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11(3): 480-96.

[6] World Health Organization. Handbook for clinical management of dengue. Geneva: World Health Organization; 2012. [Online] Available from: http://www.wpro.who.int/mvp/documents/handbook_for_clinical_management_of_dengue.pdf [Accessed on 12th January, 2015]

[7] Alexander N, Balmaseda A, Coelho IC, Dimaano E, Hien TT, Hung NT, Nishiura H, Halstead SB. Natural history of dengue virus (DENV)-1 and DENV-2 infection with high serum levels of soluble thrombomodulin and VEGF in patients with dengue fever and dengue hemorrhagic fever. Int J Clin Exp Med 2014; 7(2): 370-8.

[8] Kuan GLK, Hin YM, Isa RM. Comparison of vomiting and diarrhoea frequency among dengue-infected patients. J Coast Life Med 2015; 3(8): 616-20.

[9] Pawitan JA. Dengue virus infection: predictors for severe dengue. Acta Med Indones 2011; 43(2): 129-35.

[10] Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010; 338: 67-82.

[11] Babb K, Carrington CV, Monteil MA. A preliminary study of neopterin as a potential marker for severe dengue virus infection. Trans R Soc Trop Med Hyg 1999; 93: 447-8.

[12] Chan CP, Choi JW, Cao KY, Wang M, Gao Y, Zhou DH, et al. Multicentre prospective study on dengue classification in four South-East Asian and three Latin American countries. Trop Med Int Health 2011; 16(8): 936-48.

[13] Kuan GL, Hin YM, Isa RM. Comparison of vomiting and diarrhoea frequency among dengue-infected patients. J Coast Life Med 2015; 3(8): 616-20.

[14] Pawitan JA. Dengue virus infection: predictors for severe dengue. Acta Med Indones 2011; 43(2): 129-35.

[15] Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010; 338: 67-82.

[16] Babb K, Carlington CV, Monteil MA. A preliminary study of neopterin as a potential marker for severe dengue virus infection. Trans R Soc Trop Med Hyg 1999: 93: 447-8.

[17] Chan CP, Choi JW, Cao KY, Wang M, Gao Y, Zhou DH, et al. Detection of serum neopterin for early assessment of dengue virus infection. J Infect 2006; 53(3): 152-8.

[18] Widjaja H, Mantik MFJ. Effect of dengue hemorrhagic fever on thrombomodulin level. Paediatr Indon 2009; 49(5): 259-63.

[19] Srikiatkhachorn A, Krautrasche A, Ratanapramuk W, Wongtaptitd L, Nithipanya N, Kalayanaroj S, et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J 2007; 26(4): 283-90.

[20] Murgue B, Cassar O, Deparis X. Plasma concentrations of sVCAM-1 and severity of dengue infections. J Med Virol 2001; 65(5): 97-104.

[21] Koraka P, Murgue B, Deparis X, van Gorp EC, Setiati TE, Oepsteijn AS, et al. Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. J Med Virol 2004; 72(3): 445-50.

[22] Butteph P, Chunhakan S, Tangnararatchaik J, Yoksan S, Patanapanasat K, Chuaunsumrit A. Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. Pediatr Infect Dis J 2006; 25(10): 894-7.

[23] Sosothikul D, Seksarn P, Pongseawalan S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with dengue virus infection. Thromb Haemost 2007; 97(4): 627-34.

[24] Wojciechowska C, Wodniecki J, Wojnicz R, Romuk E, Jache W, Tomask A, et al. Neopterin and beta-2 microglobulin relations to immunity and inflammatory status in nonischemic dilated cardiomyopathy patients. Mediators Inflamm 2014; 2014: 1-8.

[25] Aleksandrovka K, Chuang SC, Boeing H, Zao H, Tell GS, Pischof T, et al. A prospective study of the immune system activation biomarker neopterin and colorectal cancer risk. J Natl Cancer Inst 2015; doi: 10.1093/jnci/djv010.

[26] Del Moral-Hernández O, Martínez-Hernández NE, Mosso-Pani MA, Hernández-Sotelo D, Illades-Aguilar B, Flores-Alfaro E, et al. Association DENV1 and DENV2 infection with high serum levels of soluble thrombomodulin and VEGF in patients with dengue fever and dengue hemorrhagic fever. Int J Clin Exp Med 2014; 7(2): 370-8.

[27] Sathupan P, Khongphattanyothin A, Srissai J, Srikaew K, Poonvarawan Y. The role of vascular endothelial growth factor leading to vascular leakage in children with dengue virus infection. Ann Trop Paediatr 2007; 27(3): 179-84.

[28] Kumar Y, Liang C, Bo Z, Rajapakse JC, Ooi EE, Tannenbaum SR. Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. PLoS Negl Trop Dis 2012; 6(11): e1887.

[29] Furuta T, Murao LA, Lan NT, Huy VT, Huong VT, Thu TT, et al. Association of mast cell-derived VEGF and proteases in dengue shock syndrome. PLoS Negl Trop Dis 2012; 6(2): e1505.

[30] Van de Weg CA, Pannuti CS, van den Ham HI, de Araujo ES, Boas LS, Felix AC, et al. Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection. J Clin Virol 2014; 60(4): 328-35.

[31] Srikiatkhachorn A, Ajariyakhajom C, Eddy TP, Kalayanarooj S, Libraty DH, Green S, et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic fever. J Virol 2007; 81(4): 1592-600.

[32] Orsi FA, Angelari RN, Mazetto BM, Quaino SK, Santiago-Bassora F, Castro V, et al. Reduced thrombin formation and excessive fibrinolysis are associated with bleeding complications in patients with dengue fever: a case–control study comparing dengue fever patients with and without bleeding manifestations. BMC Infect Dis 2013; 13(1): 350.

[33] Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, et al. Coagulation abnormalities in dengue hemorrhagic fever: serial investigations in 167 Vietnamese children with dengue shock syndrome. Clin Infect Dis 2002; 35(3): 277-85.

[34] Ernawati Dewi B, Takasaki T, Sudiro TM, Nelwan NH, Kurane I. Elevated levels of soluble tumour necrosis factor receptor 1, thrombomodulin and soluble endothelial cell adhesion molecules in patients with dengue haemorrhagic fever. Dengue Bull 2007; 31: 103-10.

[35] Biswas A, Suneesh K, Gulera R, Wig N, Sreenivas V, Aggarwal P, et al. Pathogenesis of severity in DF/DHF/DSS: a case control study. In: The Third International Conference on Dengue and Dengue Haemorrhagic Fever Global Dengue: Challenges and Promises; 2013 Oct 21-23; Bangkok, Thailand. p. 77.

[36] Liao BL, Yang SJ, Huang CH, Chen LH, Lin Y, Huang WC, et al. Serum levels of soluble vascular cell adhesion molecules may correlate with the severity of dengue virus-1 infection in adults. Emerg Microbes Infect 2015; 4: e24.

[37] Mangione JNA, Huy NT, Lan NTP, Mbanefo EC, Ha TTN, Bao LQ, et al. The association of cytokines with severe dengue in children with dengue shock syndrome. J Med Virol 2011; 83(1): 199-203.

[38] Mairuhu AT, Peri G, Setiati TE, Hack CE, Koraka P, Soemartini A, et al. Elevated plasma levels of the long pentraxin, pentraxin 5, in severe dengue virus infections. J Med Virol 2005; 76(4): 547-52.